Today, the CAO of Globus Medical (NYSE: GMED), Steven Payne, sold shares of GMED for $1.16M.
Following Steven Payne’s last GMED Sell transaction on December 18, 2017, the stock climbed by 17.0%.
See today’s analyst top recommended stocks >>
Based on Globus Medical’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $174 million and quarterly net profit of $39.54 million. In comparison, last year the company earned revenue of $156 million and had a net profit of $28.71 million. GMED’s market cap is $5.44B and the company has a P/E ratio of 47.02. Currently, Globus Medical has an average volume of 1.13M.
Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $58.67, reflecting a -4.3% downside.
The insider sentiment on Globus Medical has been negative according to 13 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Steven Payne’s trades have generated a -30.9% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments.
